Clinical Trial

Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The aim of this study is to involve high-risk patients with a history of malignant transformation in oral potentially malignant disorders. We will use a combination of Cardunil and all-trans retinoic acid for intervention. The effectiveness and safety of the combination therapy will be evaluated in the treatment of high-risk oral potentially malignant disorders, including the prevention of oral cancer recurrence and treatment of oral potentially malignant disorders. The findings of this study will provide evidence for tertiary prevention of oral cancer and the treatment of oral potentially malignant disorders.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-12-08.
Status change: Recruiting → Active, Not Recruiting 2025-02-20
Trial Details
NCT Number NCT06728631
Lead Sponsor Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Conditions Oral Cavity Cancer, Premalignant Lesion
Enrollment 22 participants
Start Date 2020-06-30
Primary Completion 2023-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-24